IP Library › Granted Patent US 9,045,557
Granted Patent B2
US 9,045,557 · App. 13/256,580 · Granted Jun 2, 2015

NEIL3 peptides and vaccines including the same

Inventors: Takuya Tsunoda (Kanagawa, JP); Ryuji Ohsawa (Kanagawa, JP); Sachiko Yoshimura (Kanagawa, JP); Tomohisa Watanabe (Kanagawa, JP); Yusuke Nakamura (Tokyo, JP); Yoichi Furukawa (Tokyo, JP)
Assignee: ONCOTHERAPY SCIENCE, INC.
C07K14/4748A61K39/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,045,557
App. No.
13/256,580
Granted
Jun 2, 2015
Kind
B2
Abstract

The present invention provides isolated peptides or the fragments derived from SEQ ID NO: 45, which bind to an HLA antigen and induce cytotoxic T lymphocytes (CTL). The peptides may include the above mentioned amino acid sequence with substitution deletion, or addition of one, two, or several amino acids sequences. The invention also provides pharmaceutical compositions including these peptides. The peptides of this invention can be used for diagnosing or treating cancer.

Claims (12)

1. A method of inducing an immune response against cancer overexpressing NEIL3 in a subject, the method comprising administering to the subject a composition comprising a peptide selected from the group consisting of:

(a) an isolated peptide of less than 15 amino acids comprising the amino acid sequence of SEQ ID NO: 5;

(b) an isolated peptide consisting of an amino acid sequence of SEQ ID NO: 5, in which 1 or 2 amino acid(s) are substituted, deleted, or added, wherein the peptide has CTL inducibility.

2. The method of claim 1 , wherein the cancer is selected from the group consisting of bladder cancer, breast cancer, cervical cancer, cholangiocellular carcinoma, colorectal cancer, endometriosis, esophagus cancer, liver cancer, NSCLC, osteosarcoma, pancreatic cancer, prostate cancer, renal carcinoma, SCLC, soft tissue tumor, AML and CML.

3. The method of claim 1 , wherein the wherein the dosage of the peptide is 0.1 mg to 10 mg.

4. The method of claim 1 , wherein the peptide is administered in combination with an adjuvant.

5. The method of claim 4 , wherein the adjuvant is incomplete Freund's adjuvant.

6. The method of claim 1 , wherein the peptide is administered by subcutaneous injection.

7. The method of claim 1 , wherein the peptide consists of the amino acid sequence of SEQ ID NO: 5.

8. The method of claim 1 , wherein the peptide has one or both of the following characteristics:

(a) the second amino acid from the N-terminus of the amino acid sequence of SEQ ID NO: 5 is substituted with leucine or methionine; and

(b) the C-terminal amino acid of the amino acid sequence of SEQ ID NO: 5 is substituted with leucine.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 28, 2011
From: TSUNODA, TAKUYA; OHSAWA, RYUJI; YOSHIMURA, SACHIKO; WATANABE, TOMOHISA
To: ONCOTHERAPY SCIENCE, INC.
Reel/Frame 027455/0283 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 28, 2011
From: NAKAMURA, YUSUKE; FURUKAWA, YOICHI
To: THE UNIVERSITY OF TOKYO
Reel/Frame 027455/0314 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 28, 2011
From: THE UNIVERSITY OF TOKYO
To: ONCOTHERAPY SCIENCE, INC.
Reel/Frame 027455/0316 →
Continuity (2)
Provisional Application 61210512 · Mar 18, 2009
Related Publication 20120093845A1 · Apr 19, 2012